Wellbutrin
Hepatic Fibrosis
Carmen DietvorstPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Hepatic Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hydronidone Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | BB |
Emricasan Conatus Pharmaceuticals Inc. | Phase 2 | CCC |
Multiple Vitamins Injection Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 2 | CCC |
Same molecule, other indications
Wellbutrin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →